Genelux Co. (NASDAQ:GNLX) VP Sells $14,519.88 in Stock

Genelux Co. (NASDAQ:GNLX) VP Yong Yu sold 6,849 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $2.12, for a total transaction of $14,519.88. Following the completion of the transaction, the vice president now directly owns 10,869 shares of the company’s stock, valued at approximately $23,042.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Genelux Trading Up 14.7 %

NASDAQ GNLX opened at $2.49 on Thursday. The company has a fifty day simple moving average of $2.85 and a two-hundred day simple moving average of $6.33. The stock has a market cap of $85.53 million, a P/E ratio of -2.57 and a beta of -1.58. Genelux Co. has a 12-month low of $1.71 and a 12-month high of $35.15.

Genelux (NASDAQ:GNLX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.08). The firm had revenue of $0.01 million for the quarter. As a group, sell-side analysts forecast that Genelux Co. will post -0.86 earnings per share for the current year.

Wall Street Analyst Weigh In

GNLX has been the subject of a number of research analyst reports. Benchmark decreased their price target on shares of Genelux from $30.00 to $25.00 and set a “speculative buy” rating for the company in a report on Friday, May 31st. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Genelux in a report on Monday, May 13th.

Institutional Trading of Genelux

A number of hedge funds and other institutional investors have recently made changes to their positions in GNLX. Woodward Diversified Capital LLC increased its stake in shares of Genelux by 2,326.2% in the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after acquiring an additional 1,037,663 shares during the period. Vanguard Group Inc. increased its stake in shares of Genelux by 1,660.1% in the third quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock worth $24,025,000 after acquiring an additional 925,258 shares during the period. Clarity Capital Partners LLC acquired a new stake in shares of Genelux in the fourth quarter worth $364,000. KWB Wealth acquired a new stake in shares of Genelux in the fourth quarter worth $327,000. Finally, San Luis Wealth Advisors LLC acquired a new stake in Genelux during the fourth quarter valued at $326,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.